Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aprinocarsen + carboplatin + gemcitabine
- Development stage
- Preclinical
- Lead developer
- Ionis Pharmaceuticals
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
The combination of aprinocarsen, carboplatin, and gemcitabine is an investigational regimen for cancer treatment. **Carboplatin** is a platinum-based chemotherapy agent that forms DNA crosslinks, inhibiting DNA replication and transcription. **Gemcitabine** is a nucleoside analog that inhibits DNA synthesis by incorporating into DNA and RNA chains, leading to chain termination. **Aprinocarsen** (also known as ISIS 3521) is an antisense oligonucleotide targeting protein kinase C-alpha (PKC-α), designed to inhibit the expression of PKC-α mRNA, thereby potentially reducing tumor cell proliferation and survival. This combination has been explored in clinical trials for advanced cancers such as non-small cell lung cancer (NSCLC) or other solid tumors where platinum-based doublets are standard therapy[2][3]. The rationale for combining these agents includes targeting multiple pathways involved in tumor growth and resistance.
- Brand names
- GemCarbo
- Other names
- gemcitabine and carboplatinGemCarbo
02
Targets
RNR (Ribonucleotide reductase)DNAPRKCA (Protein kinase C alpha)DNA polymerase family
Beyond the preview
Go deeper on aprinocarsen + carboplatin + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aprinocarsen + carboplatin + gemcitabine.